2025
October: We are pleased to announce that the Kodadek Laboratory has won the world-wide Merck KGaA Innovation Challenge and will collaborate with Merck’s Molecular Pharmacology group on the development of novel molecular glue degraders.
August: We wish the best to Dr. Weijun Gui, who is leaving the lab to start his own laboratory in the Dept. of Chemistry at Syracuse University.
August: Congratulations to Dr. Weijun Gui and graduate student Allison Goss for the publication of their paper in the J. Amer. Chem. Soc. This study describes a powerful system with which to discover non-inhibitory ligands for enzymes that modify other proteins, such as E3 Ubiquitin ligases. We anticipate that this system will be a rich source of building blocks for the construction of PROTACs and other types of chemical dimerizers.
Gui, W., Goss, A. and Kodadek, T. (2025) “A functional assay for mining non-inhibitory enzyme ligands from one bead one compound libraries: application to E3 ubiquitin ligases” J. Amer. Chem. Soc. 147, 31630-31636.
July: Congratulations to Dr. Isuru Jayalanth and our co-workers for publication in the J. Med. Chem. Of a novel method for the discovery of low affinity, low molecular weight protein-binding fragments.
Jayalath, I.M., Beckwith, D., Tong, J., Yoon, J., Liu, X. and Kodadek, T. (2025) “Exploiting avidity effects for the discovery of low affinity protein-binding fragments” J. Med. Chem. 68, 19521-19535.
2024
July: We wish Dr. Skander Abboud well as he leaves the laboratory to being his own lab at the University of North Carolina – Wilmington. Good luck!
May: Congratulations to Dr. Bo Li, Joel Tong and Josh Parker on the publication of their paper “Synthesis of membrane-permeable macrocyclic peptides via Imidazopyridimium grafting” in the Journal of the American Chemical Society.
2023
November: Congratulations to graduate student, Madeline (Maddie) Balzarini, for completing her Ph.D., with the Skaggs Graduate School of Chemical and Biological Sciences.
October: Kodadek Laboratory awarded an NIH Transformative RO1 grant to develop Ubiquitin-independent degraders.
The NIH/NCI has announced that the Kodadek Laboratory will receive a five year, $4.1 M grant to develop drug candidates that catalyze the destruction of target proteins by recruiting them directly to the proteasome. This award is from the Office of the Director’s program to fund “exceptionally innovative and impactful science”.